Topirva Tablet

About Topirva 25 mg Tablet

Topirva 25 mg Tablet is a prescription medicine containing topiramate, used to treat epilepsy in adults and children. It is taken as part of a treatment plan set by a doctor, and the dose is decided by the doctor.

There are 9 brands of Topiramate listed in Bangladesh. 2 of them have a lower unit price than Topirva. The lowest listed price is Topmate 100 mg Tablet at ৳ 1 per unit.

What is Topirva 25 mg Tablet?

Topirva 25 mg Tablet is an anti-epileptic medicine. It contains topiramate and is made by Incepta Pharmaceuticals Ltd. It is used to treat epilepsy, including certain types of seizures. It may be prescribed alone or with other anti-epileptic medicines. The doctor decides the dose and course for each person. Topiramate works in the brain to help control seizures, though its exact actions are not fully understood. The tablet is available in a 25 mg strength in a pack of 5 x 10. Always follow the doctor's instructions and do not change the dose without asking the doctor.

Uses of Topirva

Topirva 25 mg Tablet is used for epilepsy. It can be prescribed as the only anti-epileptic medicine in adults and children with newly diagnosed generalised tonic-clonic seizures or partial seizures, with or without secondarily generalised seizures. It can also be added to other anti-epileptic medicines when those alone do not control seizures well. The doctor decides whether it is suitable and how it should be used. Ask the doctor if you have questions about what it is being used for in your case.

How to use Topirva

Take Topirva 25 mg Tablet exactly as the doctor tells you. The doctor decides the dose, how often to take it, and how long to continue. Swallow the tablet with water, with or without food, unless the doctor says otherwise. Do not stop taking it suddenly or change the dose on your own, because stopping an anti-epileptic medicine quickly can increase the chance of seizures. If you miss a dose, ask the doctor or pharmacist what to do. Keep the medicine stored as directed on the pack.

Side effects of Topirva

Topirva 25 mg Tablet can cause side effects. Common ones include nausea, stomach pain, indigestion, diarrhoea, dry mouth, taste changes, weight loss, loss of appetite, tingling or numbness, headache, tiredness, dizziness, speech problems, drowsiness, trouble sleeping, and problems with memory or concentration. It can also cause anxiety, depression, or vision problems. Rarely, serious skin reactions or blood problems can occur. Call the doctor if you notice any side effect that worries you or does not go away.

Safety and precautions

Topirva 25 mg Tablet should not be used during pregnancy unless the doctor decides the benefit outweighs the risk to the unborn baby. It should not be used during breastfeeding. Tell the doctor if you are pregnant, planning a pregnancy, or breastfeeding. Also tell the doctor about any allergies, kidney problems, or other medicines you take, including alcohol and oral contraceptives, because interactions can occur. Topiramate can cause drowsiness and blurred vision, so do not drive or operate machinery if affected. The doctor will decide if it is suitable for you.

Frequently asked questions

What is the price of Topirva 25 mg Tablet?

The listed price is ৳ 5.00.

Is Topirva 25 mg Tablet safe during pregnancy or breastfeeding?

Topirva 25 mg Tablet should not be used during pregnancy unless the doctor decides the benefit outweighs the risk to the unborn baby. It should not be used during breastfeeding. Tell the doctor if you are pregnant, planning a pregnancy, or breastfeeding, so they can advise you.

What is Topirva 25 mg Tablet used for and what kind of medicine is it?

Topirva 25 mg Tablet is an anti-epileptic medicine containing topiramate. It is used to treat epilepsy, including certain types of seizures, either alone or with other anti-epileptic medicines. The doctor decides the dose and course. Ask the doctor if you have questions about what it is being used for in your case.

What side effects should I watch for with Topirva 25 mg Tablet, and when should I call the doctor?

Common side effects include nausea, stomach pain, dizziness, drowsiness, tiredness, tingling, and problems with memory or concentration. Call the doctor if you notice any side effect that worries you or does not go away, or if you have signs of a serious skin reaction, vision problems, or mood changes.

Also available as

50 mg (Tablet)

Indications

Epilepsy: Topiramate is indicated as monotherapy in adults and children aged 6 years and above with newly diagnosed epilepsy who have generalised tonic-clonic seizures or partial seizures with or without secondarily generalised seizures. Topiramate is indicated as adjunctive therapy ... Read moreEpilepsy: Topiramate is indicated as monotherapy in adults and children aged 6 years and above with newly diagnosed epilepsy who have generalised tonic-clonic seizures or partial seizures with or without secondarily generalised seizures. Topiramate is indicated as adjunctive therapy for adults and children over 2 years of age who are inadequately controlled on conventional first line antiepileptic drugs for partial seizures with or without secondarily generalised seizures; seizures associated with Lennox Gastaut Syndrome and primary generalised tonic-clonic seizures.

Migraine: Topiramate is indicated in adults for the prophylaxis of migraine headache. Prophylactic treatment of migraine may be considered in situations such as: adults experiencing three or more migraine attacks per month; frequent migraine attacks that significantly interfere with the patient's daily routine. Continuing therapy should be reviewed every six months.

Pharmacology

A seizure is an abnormal and unregulated electrical discharge occurring in the brain. This leads to a transient interruption in brain function, manifested by reduced alertness, abnormal sensations, and focal involuntary movements or convulsions. Several types of seizures exist, with common types including tonic-clonic seizures and partial onset seizures.

The exact mechanisms by which topiramate exerts pharmacological actions on seizures and migraines are currently not fully characterized. Several properties of this drug, however, are likely to contribute to its therapeutic effects. Topiramate has been observed to exert actions on voltage-dependent sodium channels, GABA receptors, and glutamate receptors.

Topiramate stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity at both AMPA and kainate receptors. Normally, GABA-A receptors are inhibitory and glutaminergic receptors are stimulatory for neuronal activity. By increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability, preventing seizures and migraines. Additionally, it blocks the voltage-dependent sodium channels, further blocking seizure activity. Topiramate has been shown to inhibit various carbonic anhydrase isozymes, but the clinical significance of this is unknown at this time.

Dosage & Administration

Epilepsy: Monotherapy:
  • Adults and children over 16 years: Titration should begin at 25 mg nightly for 1 week. The dosage should then be increased at 1- or 2-week intervals by increments of 25 or 59 mg/day, administered in two divided doses. The recommended initial target dose for topiramate monotherapy in adults with newly diagnosed epilepsy is 100 mg/day and the maximum recommended daily dose is 400 mg.
  • Children aged 6-16 years: Treatment of children aged 6 years and above should begin at 0.5 to 1 mg/kg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 0.5 to 1 mg/kg/day, administered in two divided doses. The recommended initial target dose range for topiramate monotherapy in children with newly diagnosed epilepsy aged 6 years and above is 3 to 6 mg/kg/day. Higher doses have been tolerated and rarely doses up to 16 mg/kg/day have been given.
Epilepsy: Adjunctive therapy:
  • Adults and children over 16 years: The minimal effective dose as adjunctive therapy is 200 mg per day. The usual total daily dose is 200 mg to 400 mg in two divided doses. Some patients may require doses up to 800 mg per day, which is the maximum recommended dose.
  • Children aged 2-16 years: The recommended total daily dose of Topiramate as adjunctive therapy is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome. Daily doses up to 30 mg/kg/day have been studied and were generally well tolerated.
Migraine:
  • Adults and children over 16 years: Titration should begin at 25 mg nightly for 1-week. The dosage should then be increased in increments of 25 mg/day administered at 1-week intervals. The recommended total daily dose of topiramate as treatment for the prophylaxis of migraine headache is 100 mg/day administered in two divided doses. Some patients may experience a benefit at a total daily dose of 50 mg/day.
  • Children: Topiramate in migraine prophylaxis has not been studied in children under 16 years.

Interaction

The addition of topiramate to other antiepileptic drugs (phenytoin, carbamazepine, valproic add, phenobarbitai, primidone) has no clinically significant effect on their steady-state plasma concentrations, except in some patients where the addition of topiramate to phenytoin may result in an increase of plasma concentrations of phenytoin.

CNS Depressants: Topiramate should be used with caution if used in combination with alcohol and other CNS depressants.

Oral Contraceptives: In an interaction study with a combined oral contraceptive, Topiramate increased plasma clearance of the oestrogenic component significantly. Consequently, and bearing in mind the potential risk of teratogenicity, patients should receive a preparation containing not less than 50 μg of oestrogen or use some alternative non-hormonal method of contraception. Patients taking oral contraceptives should be asked to report any change in their bleeding patterns.

Lithium: In patients with bipolar disorder, the pharmacokinetics of lithium were unaffected during treatment with Topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure (26% for AUC) following Topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with Topiramate.

Hydrochlorothiazide (HCTZ): The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of Topiramate. Clinical laboratory results indicated decreases in serum potassium after Topiramate or HCTZ administration, which were greater when HCTZ and Topiramate were administered in combination.

Metformin: Topiramate did not affect metformin tmax. The clinical significance of the effect of topiramate on metformin pharmacokinetics is unclear. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear. When Topiramate is added or withdrawn in patients on metformin therapy, careful attention should be given to the routine monitoring for adequate control of their diabetic disease state.

Pioglitazone: When Topiramate is added to pioglitazone therapy or pioglitazone is added to Topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Glibenclamide: The steady-state pharmacokinetics of Topiramate were unaffected by concomitant administration of glibenclamide. When Topiramate is added to glibenclamide therapy or glibenclamide is added to Topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Others: Topiramate, when used concomitantly with other agents predisposing to nephrolithiasis, may increase the risk of nephrolithiasis. While using Topiramate, agents like these should be avoided since they may create a physiological environment that increases the risk of renal stone formation. The interaction with benzodiazepines has not been studied. 

Valproic Acid: Concomitant administration of Topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. An association of hyperammonemia with Topiramate monotherapy or concomitant treatment with other anti epileptics has not been established.

Contraindications

Hypersensitivity to any component of this product.

Side Effects

Nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory & concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: Leucopenia, thrombocytopenia and serious skin reaction.

Pregnancy & Lactation

Topiramate should not be used during pregnancy unless, in the opinion of the physician, the potential benefit outweighs the potential risk to the foetus. Topiramate should not be used during breastfeeding.

Precautions & Warnings

In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including topiramate, should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency. Topiramate can produce central nervous system-related adverse events and may be more sedative than other antiepileptic drugs. Drowsiness is a likelihood. In addition, there have been reports of visual disturbances/blurred vision. Patients should be warned of these and advised that if affected, they should not drive, operate machinery and/or take part in activities where such reactions could put themselves or others at risk.

Overdose Effects

Topiramate overdose can result in severe metabolic acidosis. In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate in vitro. Treatment should be appropriately supportive. Haemodialysis has been shown to be an effective means of removing topiramate from the body. The patient should be well hydrated.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Topiramate

Other brands with the same generic name, cheapest first.

Topirva Tablet

50 mg

Topiramate

Incepta Pharmaceuticals Ltd.

৳ 9.8 ৳ 10.00 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.